Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO100 in High-Grade Meningioma
NCT05023018Phase 2Recruiting
- Sponsor
- NeOnc Technologies Holdings, Inc.
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Inhalation Devices, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NEO100-02 in meningioma, sponsored by NeOnc Technologies Holdings, Inc.. Started Jul 2022; status: recruiting.
02
Drugs
NEO100-02
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT05023018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023018.